创纪录!14亿美元首付款!中国最大单一创新药授权正式达成

Medaverse
Jul 27, 2025

7月24日,三生制药(01530.HK)宣布,与辉瑞就PD-1/VEGF双抗SSGJ-707达成的全球授权协议于今日正式生效。双方同意,在5月20日公司公告将获得12.5亿美元首付款的基础上,三生制药将额外获得1.5亿美元款项,以进一步授予辉瑞在中国内地独家开发和商业化SSGJ-707的权利。三生制药还将获得后续付款以及双位数的梯度分成。同时,辉瑞将认购三生制药价值1亿美元的普通股股份。(60.5...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10